Imlifidase

ConfIdeS randomized 64 participants but was open label, and its control arm allowed several desensitization approaches or continued waiting. The comparison therefore does not isolate imlifidase against one standardized active regimen. The rejection counts use denominators of 28 and 13 rather than the complete randomized population, so they should not be interpreted as randomized-population rejection risks. The reported primary comparison concerns kidney function at 12 months, not a demonstrated long-term survival benefit.

Highdes enrolled 19 participants without a randomized control group. Its primary endpoint was crossmatch conversion, which enables transplantation but does not alone establish long-term graft survival or freedom from rejection. The five-year single-site report concerns 8 participants from the same trial, not an additional independent trial population.

This unblinded study enrolled 10 participants in two dose groups of 5 and used descriptive analyses. It does not provide a randomized estimate of treatment effect. Its 52 and 54 adverse-event counts are numbers of events, not numbers of affected participants. The combined early-trial publication should not be added to this enrollment count as an independent population.

The protocol describes an exploratory open-label study that was not powered for efficacy endpoints. Planned enrollment was 20 participants, and the later sponsor update reported 17. The earlier combined publication included 14 United States participants and reported several outcomes across 25 participants from both countries. Those pooled efficacy and safety counts must not be treated as outcomes for all 17 participants in this study alone.

The presentation distinguishes a safety population of 51 imlifidase-treated participants from an intention-to-treat population of 50. Its concurrent reference cohort is explicitly non-comparative, so the reported outcomes do not constitute a randomized comparative-effectiveness estimate. Forty-eight imlifidase-treated participants completed the trial. The one-year results do not resolve longer-term graft outcomes.

This non-interventional follow-up analysis includes 39 crossmatch-positive participants from earlier trials. It is not a new randomized treatment comparison. Five-year kidney-function estimates were available for 24 functioning grafts, so these estimates are conditional on graft function and available follow-up rather than representing all original participants. The three-year, five-year, and correspondence publications concern overlapping follow-up evidence and should not be counted as separate trial populations.

This single-center report describes 7 participants, including 5 deceased-donor and 2 living-donor transplant recipients. All had functioning grafts at a median follow-up of 235 days, but 3 experienced antibody rebound and antibody-mediated rejection. The small series does not provide a randomized comparator. Its participants should not be assumed to be independent of other trial or follow-up publications without confirmation of participant overlap.

This clinical-practice cohort comprised 9 transplanted participants with at least 3 months of follow-up. The mean reported follow-up was 7 months. Crossmatch conversion occurred after one imlifidase injection, but 4 participants developed at least one infection. The small cohort and short follow-up do not establish comparative effectiveness or long-term graft survival.

The research summary describes a single-arm pediatric trial with planned enrollment of 10 participants aged 1 to 17 years. This design does not provide a randomized comparator. No study results are included in this report, so the planned study cannot establish pediatric efficacy or safety here.

The report concerns one 51-year-old woman with lupus nephritis undergoing retransplantation. The absence of donor-specific antibody rebound at six months is an individual observation, not an estimate of response probability. The case does not establish comparative efficacy or safety in other highly sensitized transplant candidates.

This report describes one recipient with preformed anti-MICA donor-specific antibodies. Antibody rebound occurred after 14 days, and early antibody-mediated rejection was reported. Later antibody removal followed immunoadsorption and daratumumab, so that outcome cannot be attributed to imlifidase alone.

This randomized study addressed treatment of established antibody-mediated rejection after transplantation, not pretransplant desensitization. Thirty participants were randomized, and the trial was open label. Greater donor-specific antibody reduction with imlifidase did not establish clinical benefit; four graft losses occurred in the imlifidase arm and one in the plasma-exchange arm. These findings should not be pooled as direct evidence for the pretransplant indication.

This single-center, open-label ascending-dose study enrolled 8 participants with chronic kidney disease. It establishes pharmacodynamic and immunogenicity observations in a small population, not a randomized estimate of transplantation benefit or long-term safety. IgG depletion within 48 hours and anti-IdeS antibody development are distinct outcomes and should not be equated with sustained clinical benefit.

The trial included 29 healthy male participants, with 20 receiving IdeS and 9 receiving placebo. No formal power calculation was performed. Although the study reported no serious adverse events, its small healthy-volunteer population does not establish safety or efficacy in highly sensitized kidney transplant candidates receiving concomitant immunosuppression.